Outlook Therapeutics (OTLK) Capital Expenditures (2015 - 2025)
Outlook Therapeutics (OTLK) posted quarterly Capital Expenditures of $1.0 for Q3 2025, up 100.0% year-over-year from $0.5 in Q3 2024, and up 100.0% quarter-over-quarter from -$22966.0 in Q3 2024.
Outlook Therapeutics (OTLK) Capital Expenditures (2015 - 2025) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Capital Expenditures for 8 consecutive years, with $1.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Capital Expenditures rose 100.0% year-over-year to $1.0; the TTM figure through Sep 2025 stood at -$24015.0 (changed 0.0% YoY), while the FY2025 annual figure was $95247.0, up 1514.36% from the prior year.
- Capital Expenditures rose to $1.0 in Q3 2025 per OTLK's latest filing, from -$22966.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $22967.0 in Q2 2024 and bottomed at -$24017.0 in Q3 2023.
- Historically, Capital Expenditures has averaged -$6003.8 across 3 years, with a median of -$11482.5 in 2024.
- Annual changes were most pronounced in 2024 — Capital Expenditures advanced 4.38% — and 2025, when it surged 100.0%.
- Outlook Therapeutics' Capital Expenditures stood at -$24017.0 in 2023, then increased by 4.38% to -$22966.0 in 2024, then jumped by 100.0% to $1.0 in 2025.
- Business Quant data shows OTLK's Capital Expenditures at $1.0 in Q3 2025, -$22966.0 in Q3 2024, and $22967.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.00 |
| Sep 30, 2025 | 1.00 |
| Sep 30, 2024 | -22,966.00 |
| Sep 30, 2024 | -22,966.00 |
| Jun 30, 2024 | 22,967.00 |
| Jun 30, 2024 | 22,967.00 |
| Sep 30, 2023 | -24,017.00 |
| Sep 30, 2023 | -24,017.00 |
| Sep 30, 2019 | 1.00 |
| Sep 30, 2019 | 1.00 |
| Jun 30, 2019 | -657,960.00 |
| Jun 30, 2019 | -657,960.00 |
| Mar 31, 2019 | 469,436.00 |
| Mar 31, 2019 | 469,436.00 |
| Dec 31, 2018 | 625,830.00 |
| Dec 31, 2018 | 625,830.00 |
| Sep 30, 2018 | 1.26 Mn |
| Sep 30, 2018 | 1.26 Mn |
| Jun 30, 2018 | 168,020.00 |
| Jun 30, 2018 | 168,020.00 |